Cytek Biosciences
CTKB
88 hedge funds and large institutions have $898M invested in Cytek Biosciences in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 10 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
58% more capital invested
Capital invested by funds: $568M → $898M (+$331M)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5.97% more ownership
Funds ownership: 39.37% → 45.34% (+6%)
5% more funds holding
Funds holding: 84 → 88 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$57.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$16.7M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$11.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.2M |
| 2 |
MGM
Miura Global Management
New York
|
-$10.8M |
| 3 |
RI
RTW Investments
New York
|
-$9.84M |
| 4 |
Millennium Management
New York
|
-$6.42M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$5.37M |
CTKB Hedge Fund Activity: Q3 2022 in Review
88 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q3 2022, worth a combined $898M — up 58% from $568M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CTKB positions and 10 closed out — a net gain of 4 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Brown Capital Management, opening a new position worth an estimated $57.2M. The largest seller was Point72 Asset Management, cutting an estimated $11.2M.
- 88 institutional investors held Cytek Biosciences (CTKB) as of Q3 2022, up from 84 in Q2 2022.
- Funds reported $898M of Cytek Biosciences stock for Q3 2022, up 58% quarter-over-quarter.
- 14 funds opened new Cytek Biosciences positions in Q3 2022 and 10 closed out, a net change of +4 holders.
- The largest Cytek Biosciences buyer in Q3 2022 was Brown Capital Management, an estimated $57.2M added.
- The largest Cytek Biosciences seller in Q3 2022 was Point72 Asset Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2022.